Cookie technology helps us bring you the best possible experience when you visit this website. Please let us know if you're happy to accept cookies. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.

en:

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • Atopic Dermatitis Home
      Articles
      Videos

      Infographics & Posters 

      alt

       

      Understanding JAK inhibitors in

      moderate-to-severe atopic dermatitis

       

      alt

       

      Mode of action of upadacitinib in the treatment of moderate-to-severe atopic dermatitis

       

      alt

       

      Upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: the Heads Up study

       


      alt

       

      Upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: Integrated results through Week 52 of the Measure Up 1 and 2 studies

       


      alt

       

      Characterization of treatment-emergent acne in patients with moderate-to-severe atopic dermatitis receiving upadacitinib

       

      alt

       

      Upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: An integrated safety analysis of 4 clinical trials over 16 weeks

       


      alt

       

      Upadacitinib: Dosing, screening, and monitoring in patients with moderate-to-severe atopic dermatitis

       


      alt

       

      Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis: Results from the Measure Up 1 and 2 studies

       

      alt

       

      Understanding the impact of atopic dermatitis on patients:

       


      alt

       

      A novel minimal disease activity (MDA) concept:

       


      AbbViePro Logo 2023

      Our therapy areas

      Oncology
      Immunology
      Medical Information
       

      Additional info

      Privacy Notice
      Terms Of Use

       

      For Oman HCPs.

      Department of Pharmacovigilance & Drug information.

      Directorate General of pharmaceutical affairs and Drug control.

      Ministry of health, Sultanate of Oman

      Phone Nos:: 22357687 / 22357686

      Fax: 22358489

      Email: [email protected]

      Website:www.moh.gov.om

       

       

      This website is intended for Gulf Healthcare Professionals

      AbbVie Biopharmaceuticals GmbH.

       

      Suite 2901, U Bora Tower,Business Bay, Dubai, UAE

      PO Box:: 118052

      OFFICE : +971 4 5506100

      FAX: +971 4 5506101

      Patient Safety is our Priority, we will remain always by your side. For Reporting Adverse events Please Contact.

      [email protected] or Hotline: 00971564135746

      JAKa-BH-00004-MC